Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2018 financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 4169558.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
